Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma Inc (NASDAQ: LUMO) is a clinical-stage biotechnology company pioneering therapies for rare endocrine disorders, with a focus on pediatric growth hormone deficiencies. This page aggregates official press releases, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and stakeholders will find timely updates on LUMO’s pipeline progress, including its lead oral growth hormone secretagogue LUM-201, regulatory milestones, and collaborative research initiatives. The curated content spans clinical data disclosures, partnership announcements, and scientific presentations relevant to rare disease therapeutics.
Key categories include Phase 2 trial results, FDA communications, intellectual property updates, and research collaborations. All materials are sourced to ensure compliance with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Lumos Pharma’s latest advancements in transforming treatment paradigms for underserved patient populations. Regularly updated to reflect the company’s evolving role in rare disease innovation.
Lumos Pharma (NASDAQ:LUMO) will have its President and Chief Scientific Officer, John McKew, participate in a panel at the Cantor Rare Disease Symposium from March 28-30, 2022. The panel, titled “New World Order for Endo/CV/Renal Diseases – Applying Precision Medicine”, is scheduled for March 29 at 1:00 PM (EDT). This discussion aims to address the shift from prevalent to rare diseases in precision medicine. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 targeting Pediatric Growth Hormone Deficiency, currently in Phase 2 trials.
Lumos Pharma (NASDAQ:LUMO) reported its financial results for 2021, ending the year with cash reserves of $94.8 million. The company is progressing with two key clinical trials: the OraGrowtH210, nearing 50% enrollment with expected interim analysis results on height velocity by late 2022, and the OraGrowtH212, also on track for interim analysis. R&D expenses increased by $7 million to $16.2 million, while G&A expenses decreased by $1.9 million to $15.3 million. The net loss grew to $30.4 million in 2021 compared to a loss of $5.7 million in 2020.
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company focused on rare diseases, will participate in two notable conferences in March 2022. The 34th Annual Roth Conference takes place from March 13-15, featuring a live fireside chat on March 14 at 10:30 AM PDT. Additionally, the Maxim 2022 Virtual Growth Conference is scheduled for March 28-30, with a pre-recorded presentation available from March 28 at 9:00 AM EDT. Investors can access the webcasts through Lumos Pharma's website and contact their investor relations for one-on-one meetings.
Lumos Pharma, a clinical-stage biopharmaceutical company (NASDAQ:LUMO), will release its full year 2021 financial results on March 10, 2022, after market close. A conference call to discuss these results and updates on clinical activities will begin at 4:30 PM ET. Investors can join via a live audio webcast or phone. Lumos Pharma is focused on developing therapies for rare diseases, with its lead candidate, LUM-201, aimed at treating Pediatric Growth Hormone Deficiency and currently undergoing clinical trials.
Lumos Pharma (NASDAQ:LUMO) will present at the H.C. Wainwright Virtual BIOCONNECT Conference from January 10-13, 2022. The presentation will be available online starting at 7:00 AM ET on January 10. Interested parties can access the webcast through Lumos Pharma's website under the Investors & Media section and it will be archived for 90 days. Lumos Pharma focuses on developing therapeutics for rare diseases, with its lead candidate LUM-201 targeting Pediatric Growth Hormone Deficiency. LUM-201 is currently undergoing Phase 2 trials and has received Orphan Drug Designation in the US and EU.
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare diseases, will participate in several upcoming investor conferences. At the Stifel 2021 Virtual Healthcare Conference on November 16, Lumos will present from 3:20-3:50 PM EST and hold one-on-one meetings. The Jefferies London Healthcare Conference, running from November 16 to 19, will feature a pre-recorded chat available November 18. Additionally, Lumos will engage at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, with a fireside chat available from November 22.
Lumos Pharma, focused on therapeutics for rare diseases, reported its Q3 2021 financial results. The company continues to advance its LUM-201 program for pediatric growth hormone deficiency (PGHD) with major progress in its OraGrowtH210 trial. With cash reserves of $100.7 million, operations are funded through critical data readouts anticipated in 2H 2023. R&D expenses rose to $4.1 million, primarily due to clinical trial costs, while general expenses dropped to $3.4 million. The net loss for Q3 2021 was $7.5 million, contrasting with a net gain of $1.8 million in Q3 2020.
Lumos Pharma, Inc. (LUMO) will announce its Q3 2021 financial results on November 3, 2021, after market close. A conference call is scheduled for 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. The public can access the live webcast via a dedicated link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its leading candidate, LUM-201, undergoing Phase 2 trials for Pediatric Growth Hormone Deficiency.
Lumos Pharma, a clinical-stage biopharmaceutical company, will participate in two major conferences in September. The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, featuring a pre-recorded presentation available from September 13 at 7:00 AM ET. Additionally, the Cantor Virtual Global Healthcare Conference is scheduled for September 27-30, with a live fireside chat on September 29 from 4:00-4:30 PM ET. Lumos Pharma focuses on developing therapeutics for rare diseases, including its lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency.
Lumos Pharma has announced key leadership changes, promoting John McKew to President and appointing David B. Karpf as Chief Medical Officer. The company reported a Q2 2021 net loss of $8.7 million, up from $5.4 million in Q2 2020, with cash reserves growing to $107.7 million. The OraGrowtH210 Trial's primary data outcome has been extended to late 2023 due to COVID-related delays. The initiation of the OraGrowtH212 Trial is also noted, alongside efforts to assess LUM-201's potential for further indications in rare diseases.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
